Cargando…

Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam

BACKGROUND: Detection of ceftazidime/avibactam (CAZ/AVI) antibacterial activity is absolutely vital with the rapid growth of carbapenem resistant Enterobacteriaceae (CRE). But now, there is no available automated antimicrobial susceptibility testing card for CAZ/AVI, so Kirby-Bauer has become an eco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xianggui, Wang, Dan, Zhou, Qin, Nie, Fang, Du, Hongfei, Pang, Xueli, Fan, Yingzi, Bai, Tingting, Xu, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824082/ https://www.ncbi.nlm.nih.gov/pubmed/31675928 http://dx.doi.org/10.1186/s12866-019-1613-5

Ejemplares similares

Kirby-Bauer disc approximation to detect inducible third-generation cephalosporin resistance in Enterobacteriaceae
por: Qin, Xuan, et al.
Publicado: (2004)

Analysis of the Clinical Effect of Combined Drug Susceptibility to Guide Medication for Carbapenem-Resistant Klebsiella pneumoniae Patients Based on the Kirby–Bauer Disk Diffusion Method
por: Yao, Huijuan, et al.
Publicado: (2021)

2068. Evaluation of Ceftazidime-Avibactam Disks from Different Commercial Manufacturers for Susceptibility Testing against Meropenem Nonsusceptible Enterobacteriaceae
por: Lin, Lynn-Yao, et al.
Publicado: (2018)

A Twist to the Kirby-Bauer Disk Diffusion Susceptibility Test: an Accessible Laboratory Experiment Comparing Haloferax volcanii and Escherichia coli Antibiotic Susceptibility to Highlight the Unique Cell Biology of Archaea
por: Schiller, Heather, et al.
Publicado: (2022)

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
por: Rahmati, Elham, et al.
Publicado: (2017)

A New Twist to the Kirby-Bauer Antibiotic Susceptibility Test Activity—Increasing Antibiotic Sensitivity of Pseudomonas fluorescens through Thermal Stress
por: Gerbig, Donald G., et al.
Publicado: (2013)

Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae
por: Alraddadi, Basem M., et al.
Publicado: (2019)

621. In vitro Ceftazidime: Avibactam Resistance in Carbapenem-Resistant Enterobacteriaceae Isolates
por: Belal, Maymonah, et al.
Publicado: (2019)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)

Clinical Outcome of Patients on Ceftazidime–Avibactam and Combination Therapy in Carbapenem-resistant Enterobacteriaceae
por: Nagvekar, Vasant, et al.
Publicado: (2021)

Ceftazidime-avibactam and Meropenem Double Disk Diffusion Test for Identifying Carbapanem-Resistant Enterobacteriaceae and Distinguishing Between Serine and Metallo-β-Lactamase Producing Organisms
por: Lin, Lynn-Yao, et al.
Publicado: (2017)

Cost-effectiveness analysis of ceftazidime avibactam versus colistin in carbapenem-resistant enterobacteriaceae in Iran
por: Goudarzi, Zahra, et al.
Publicado: (2023)

Ceftazidime/avibactam for specified infections
Publicado: (2020)

2262. Ceftazidime–Avibactam vs. Polymyxin B in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
por: John, Jamie, et al.
Publicado: (2019)

Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation
por: Dai, Yuanyuan, et al.
Publicado: (2021)

Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
por: Han, Renru, et al.
Publicado: (2023)

1885. Cost-Effectiveness of Ceftazidime–Avibactam Compared With Colistin for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia
por: Sfeir, Maroun, et al.
Publicado: (2018)

1826. Impact of Rapid Diagnostics and Ceftazidime–Avibactam on Mortality after Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae
por: Satlin, Michael J, et al.
Publicado: (2019)

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China
por: Cui, Xiaoyan, et al.
Publicado: (2020)

Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria
por: DUMLU, Rıdvan, et al.
Publicado: (2022)

Evaluation of the Etest and disk diffusion method for detection of the activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa in China
por: Wang, Qi, et al.
Publicado: (2020)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam
por: Xiong, Luying, et al.
Publicado: (2022)

In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015–17)
por: Spiliopoulou, Iris, et al.
Publicado: (2020)

1385. Efficacy of Ceftazidime–Avibactam in Combination with Aztreonam (COMBINE): Solutions for Metallo-β-Lactamase Producing-Enterobacteriaceae (MBL)
por: Lodise, Thomas P, et al.
Publicado: (2018)

Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study
por: Rathish, Balram, et al.
Publicado: (2021)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
por: Cortazzo, Venere, et al.
Publicado: (2022)

1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018)

Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis
por: Prayag¹, Parikshit S, et al.
Publicado: (2023)

Comparative Evaluation of Antimicrobial Efficacy of Herbal Formulations of Septilin and Triphala with Conventional 2% Chlorhexidine on Root Canal and Oral Commensal Bacteria using Kirby Bauer Method: An in-vitro Study
por: Ahmed, Shadab, et al.
Publicado: (2022)

In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
por: Zou, Chunhong, et al.
Publicado: (2020)

In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018)
por: Piérard, D., et al.
Publicado: (2021)

In Vitro Susceptibility of Burkholderia pseudomallei Isolates to Cefiderocol and Ceftazidime/Avibactam from Odisha, India
por: Jena, Jayanti, et al.
Publicado: (2023)

In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates
por: Lim, Tze-Peng, et al.
Publicado: (2023)

Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study
por: Zheng, Guanhao, et al.
Publicado: (2021)

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment
por: Wang, Lin, et al.
Publicado: (2022)

Reproducibility of Ceftazidime/Avibactam MIC Results for Enterobacteriaceae and Pseudomonas aeruginosa Using MicroScan Dried Gram Negative MIC Panels
por: Humphries, Romney, et al.
Publicado: (2017)

Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam
por: Jorgensen, Sarah C. J., et al.
Publicado: (2020)

2246. Improved Outcomes for Cancer Patients Treated With Ceftazidime–Avibactam vs. Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia
por: Borjan, Jovan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d2l63ggohriksj32vqmmcpsjar